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Abstract: 
Introduction: Diffusion tensor imaging (DTI) may be helpful in assessing optic pathway integrity 
as a marker for treatment in neurofibromatosis type 1 (NF1) patients with optic gliomas (OG).  However, 
susceptibility artifacts are common in typical single-shot echo planar imaging (ssDTI).  A readout-
segmented multi-shot EPI technique (rsDTI) was utilized to minimize susceptibility distortions of the 
skull base and improve quantitative metrics.  
Methods:  Healthy controls, children with NF1 without OG, and NF1 with OG ± visual symptoms 
were included.   All subjects were scanned with both rsDTI and ssDTI sequences sequentially. Diffusion 
metrics and deterministic fiber tracking were calculated. Tract count, volume, and length were also 
compared by a two-factor mixed ANOVA.   
Results: 5 healthy controls, 7 NF1 children without OG, and 12 NF1 children with OG were 
imaged. 6 OG patients had visual symptoms.  4 subjects had no detectable optic pathway fibers on ssDTI 
due to susceptibility, for which rsDTI was able to delineate. Tract count (p<0.001), tract volume 
(p<0.001) and FA (P<0.001) were significantly higher for rsDTI versus ssDTI for all subjects. MD (p<0.001) 
and RD (p<0.001) were significantly lower for rsDTI vs ssDTI. Finally, MD, AD, and RD had a significantly 
lower difference in NF1 children with visual symptoms compared to NF1 children without visual 
symptoms only on ssDTI scans. 
Conclusion: DTI with readout-segmented multi-shot EPI technique can better visualize the optic 
pathway and allow more confident measurements of anisotropy in NF1 patients.  This is shown by a 
significant increase in FA, tract count, and volume with rsDTI versus ssDTI. 
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Children with neurofibromatosis type 1 (NF1) have up to a 20% incidence of developing optic 
pathway glioma (OG) with visual loss affecting up to 50% of these patients with glioma. Visual symptoms 
include loss of visual acuity, proptosis, strabismus and nystagmus [1,2,3].  First line treatment for OG 
includes chemotherapy which can improve visual acuity in 32% of treated patients [1].  However, the 
clinical indication for initiating adjuvant therapy in a patient with an OG detected by imaging is not clear, 
particularly without detectable visual deficits. Although optic chiasm volume can correlate with visual 
acuity in other patient populations [4]; within NF1 patients there is poor correlation of the radiographic 
size of tumors and visual outcomes [1]. Furthermore, there is difficulty in assessing visual function in 
very young children who cannot adequately communicate deteriorating visual symptoms or cooperate 
with visual assessment tests. This is particularly relevant in NF1 patients where the mean age of 
diagnosis of OG is between 2-5 years of age [5, 6]. As such, an imaging marker of visual function in NF1 
patients may be helpful in determining a threshold point for treatment, as well as to monitor treatment 
response.   
Diffusion tensor imaging (DTI) is an MRI technique which provides a quantitative evaluation of 
the white matter tracts and may be helpful in assessing optic pathway integrity as an imaging marker for 
treatment in these patients.  However, susceptibility artifacts that are common in typical DTI single-shot 
echo planar imaging (ssDTI) can severely distort areas of interest such as the optic nerves and optic 
chiasm, which are immediately adjacent to the air-bone interface from the sinuses and skull base. In 
addition to susceptibility induced distortion, the optic nerve is a small structure of less than 3mm and 
requires high spatial resolution for proper imaging.  One solution to reducing susceptibility artifacts on 
DTI is to utilize a readout-segmented multi-shot echo-planar-imaging technique (rsDTI), which has 
shown improved visualization of DWI images in the skullbase particularly for sinonasal lesions [7]. 
The purpose of this research is to compare diffusion tensor MRI of the optic nerve between 
ssDTI and rsDTI in healthy volunteers, NF1 patients without OG, and NF1 patients with OG with and 
without visual symptoms. We hypothesize that rsDTI will be superior to ssDTI both qualitatively and in 
measured quantitative parameters due to less susceptibility artifact. 
 Participants and Methods: 
The prospective study was approved by the Indiana University institutional review board.  
Written informed consent was obtained from patients greater than or equal to 18 years of age or from 
parents/legal guardians of children less than 18 years, with child assent when appropriate according to 
institutional policy.   
Healthy children (HC) without a history of NF1 or visual symptoms, children with NF1 without 
OG, and NF1 with OG with and without visual symptoms were recruited. Healthy controls were recruited 
through advertisements and were screened for past medical history, surgery or visual symptoms with a 
patient questionnaire. Patients with prior cancers, chemotherapeutic treatment and visual symptoms 
were excluded.   NF1 patients were recruited from a pediatric NF1 clinic. Visual symptoms and 
concurrent chemotherapy treatment history were obtained from an electronic patient database. The 
existence of an optic pathway tumor was determined by prior MRI results. OG was defined as an 
enhancing or nonenhancing optic pathway mass that abnormally expanded the optic pathway compared 
to the contralateral side.  All NF1 patients with OG had an opththalmology referral for visual symptom 
assessment.  
Both rsDTI and ssDTI were obtained sequentially in the same scan session.  Diffusion images 
were acquired on 3T scanners (Verio and Skyra, Siemens MAGNETOM, Erlangen, Germany) with the 
following parameters for product ssDTI (Verio/Skyra; TR: 4200/2500ms, TE: 152/86ms, Bandwidth: 
1085/1210, Echo Spacing: 0.94ms, Flip Angle:90, Matrix:192x192/180x180, no gap, IPAT=2) and rsDTI 
using readout segmentation of long variable echo-trains (RESOLVE; Siemens, Erlangen, Germany) 
(TR:2800/2320ms, TE:70/68ms, Bandwidth723/770:, Echo Spacing: 0.32ms, Flip Angle:90, 
Matrix:192x192/180x180, no gap, IPAT=2). For both sequences, 12 directions at each diffusion-
weighting strength of b-250, 500, and 800 s/mm2 (voxel: 1.3 x 1.3 x 2.2mm) for 16 axial slices centered 
over the optic chiasm with oblique sagittal rotation to include the optic nerves, tracts and as much of 
the optic radiations as possible. To match acquisition time for the rsDTI images, 6 averages were 
acquired for the ssDTI scan. RsDTI required 12 minutes 10 seconds to perform and ssDTI required 12 
minutes and 19 seconds. At our institution, sedation for clinical MRI exams are routinely used for 
children from 3 months to 7 years of age. Exams were excluded if there was motion degradation as 
determined by a board certified neuroradiologist (CH, 10 years of experience).  
B0 maps for ssDTI and rsDTI in all subjects were qualitatively evaluated by the board certified 
neuroradiologist (CH) blinded to the DTI technique used based on a 5-point Likert scale. A score of 1 
represents optic pathways completely obscured by susceptibility artifact to a score of 5, which 
represents no distortion. Two-tailed Wilcoxon signed ranks test was used to assess for a significant 
difference between the two techniques. 
Diffusion metrics (Fractional Anisotropy: FA, Mean Diffusivity: MD, Axial Diffusivity: AD, and 
Radial Diffusivity: RD) were computed and deterministic fiber tracking [8] were performed using DSI 
Studio (http://dsi-studio.labsolver.org). A seeding region was placed at both the right or left optic 
radiations, approximately 5 millimeters posterior to the optic chiasm, and a secondary inclusion region 
of interest (ROI) was placed on the optic chiasm (seeding: 10000, angular threshold: 60 degrees, step 
size: 0.6 mm, track minimum length 30 mm).  All ROIs were placed on the FA maps. All ROIs were placed 
by a trained analyst (RD) in conjunction with a board certified neuroradiologist (CH). For tumors 
involving the chiasm, tract or radiations, ROIs were placed within the tumor at the expected epicenter of 
the native optic pathway (Figure 1). To focus only on the effects of the ssDTI geometric distortion on the 
optic nerves, both tracts originating from the left and right optic radiations were merged and cut at the 
narrowest coronal plane of the optic chiasm and posterior optic radiations were removed (Figure 
2).  Scans with too much susceptibility distortion to result in any successful tract fibers was considered a 
zero for tract count, volume and length.  
Tract count, volume, and length along with diffusion metrics were compared. Two-factor mixed 
analysis of variance was used to accommodate for both within group comparisons (between ssDTI and 
rsDTI within group patients) as well as between group comparisons (between tumor or visual symptom 
groups and healthy controls) using SPSS linear mixed model.  Tract and diffusion metrics were normally 
distributed and tested with Shapiro-Wilk except for tract length (p<0.01).  Due to small sample sizes, 
multiple comparison corrections were not performed, and all data points were kept for statistical 
analysis.  A two tailed t-test was used to assess for significant differences between the NF1 patients who 
had chemotherapy compared to NF1 patients without chemotherapy. Finally, observed power and 
effect size reported as partial eta2 (IBM SPSS 24).   
Results:  
Clinical Characteristics 
A total of 5 healthy children, 7 children with NF1 without OG, and 12 children with NF1 with OG 
were imaged. Age range was 2 to 18 years of age (mean 8.9 years, 12 females). 11 patients required 
sedation for the exam, and no exams were excluded due to motion. Of the patients with OG, 6 had 
visual symptoms (Table 1). A total of seven subjects had concurrent or a history of chemotherapy. Two 
subjects had concurrent chemotherapy with vincristine and carboplatin during the time of scan. Four 
subjects had 1.5-6 years of previous vincristine and carboplatin and one subject had a course of sunitinib 
malate two years prior to therapy for the treatment of a plexiform neurofibroma as part of an 
investigational clinical trial.  
Qualitative Likert Scale 
Figure 3 shows the less susceptibility distortion on FA maps for rsDTI compared to ssDTI. One 
subject had no detectable optic pathway fibers bilaterally, two subjects had no left optic nerve and one 
subject had no right optic nerve fibers detected on ssDTI. Qualitative evaluation using a Likert scale 
demonstrated a significantly greater mode and median for rsDTI (3, range 3[5-2]) compared to ssDTI (2, 
range 4[5-1], p<0.001), indicating that rsDTI had better subjective visualization of the optic pathway and 
less distortion. 
RsDTI vs ssDTI – All subjects 
In all subjects, rsDTI was able to delineate fibers for each optic nerve. For all subjects including 
healthy controls, rsDTI had significantly increased tract count, tract length, tract volume, and FA 
compared to ssDTI. Furthermore, rsDTI had significantly decreased MD, AD, and RD compared to ssDTI 
(Table 2). 
RsDTI vs ssDTI – within groups 
When comparing within subject groups for HC, NF1 with OG and NF1 without tumor, rsDTI 
continued to produce significantly greater tract count, tract volume and FA for the NF1 subject groups. 
Significantly decreased MD and RD was seen for rsDTI vs ssDTI within the NF1 group without tumor and 
significantly decreased MD, AD and RD for the NF1 group with tumor. However, tract count, length and 
volume were not significantly different in HC between the two techniques (Table 3).  
When comparing within subject groups for HC, NF1 without visual symptoms and NF1 with 
visual symptoms, significant increase in tract count and volume were noted in the NF1 with and without 
visual symptom groups between the two DTI techniques. FA was significantly increased in all groups 
between the two techniques. MD, AD, and RD was significantly decreased in rsDTI compared to ssDTI for 
the NF1 group without visual symptoms. Only RD was significantly decreased for rsDTI within the NF1 
with visual symptoms group. Again, tract count, length and volume were not significantly different in HC 
between the two techniques (Table 4). 
When comparing rsDTI and ssDTI within groups for NF1 with chemotherapy and NF1 without 
chemotherapy, there were similar results with significantly increased tract count, volumes and FA for 
both groups and decreased MD, AD, and RD for the NF1 no chemotherapy group for rsDTI versus ssDTI.  
(Table 5).  
Between group comparisons 
Comparisons were performed between groups within the same technique to evaluate for 
differences based on the presence of NF1, tumor, visual symptoms or chemotherapy. There was a 
significant decrease of MD, RD, and AD in the ssDTI technique between the NF1 with visual symptoms 
and NF1 without visuals symptoms (Table 6).  Similarly, NF1 patients with chemotherapy had 
significantly decreased measures of MD, AD, and RD compared to NF1 patients without chemotherapy 
only within the ssDTI technique (Table 7). No significant difference was seen across patient groups with 
the rsDTI technique (Appendix 1). 
Observed power and effect size 
 Finally, observed power and effect size were calculated for rsDTI vs ssDTI in all subjects and 
within patient groups.  Adequate power (>0.8) was noted for tract count, tract volume, FA, and RD for 
comparison of the techniques in all subjects and within groups (Table 8 and 9).  Comparison of different 
groups for the effect of NF1, tumor, visual symptoms or chemotherapy did not have adequate power 
(Table 9). 
Discussion: 
RsDTI vs ssDTI 
In our study, we were able to demonstrate the superiority of rsDTI in qualitative and 
quantitative evaluation. RsDTI was able to produce significantly improved diffusion tensor data in terms 
of tract volume and count for the optic nerves particularly when challenged by the susceptibility artifact 
of the anatomy inherent within the anterior skull base. Tract count, length and volume do not 
necessarily represent a 1:1 representation of the actual number of nerve fibers, nerve length or 
thickness, which cannot be evaluated without sacrificing the optic nerve. However, both techniques 
were processed in an identical manner, and the more robust technique with less susceptibility distortion 
can reasonably be expected to have a significantly higher result in these parameters, which we have 
demonstrated for rsDTI in both tract count and volume.   rsDTI utilizes a multishot EPI technique, in 
which signal intensity acquisition is divided into multiple shots with interleaved and concatenated k-
space trajectories. This requires a 2D navigator echo to correct for phase variations between shots 
which leads to increased scanning time but at the benefit of increased resolution and decreased 
susceptibility distortion [9, 10]. To control for scanning time, additional averages were added to ssDTI 
which would increase signal to noise as well as reduce distortion. Motion limitation of both scan types 
would be equally affected and did not invalidate any of the scans in our cohort.  
FA, which is a representation of the magnitude of the diffusion of water molecules along a single 
axis, particularly along white matter tracts, is also commonly used in the literature as a quantitative MR 
parameter for a measure of tract integrity. When comparing two techniques, a higher FA would suggest 
a tract with less disruption, presumably by artifact in our experiment. Furthermore, FA was also 
significantly higher for rsDTI within the subject groups due to greater resolution and less susceptibility 
distortion for the small optic nerve as well as less volume averaging with the cerebral spinal fluid 
surrounding the prechiasmatic optic nerves. Similarly, with similar parallel imaging acceleration, our 
data supports the theoretical expectation of approximately a third of the distortion of rsDTI (0.32ms) 
compared to ssDTI (0.94ms) based on echo spacing.  
 Jeong et al [11] recently reported using a multishot high resolution EPI vs single shot EPI 
technique for tractography on the optic nerve in fifteen healthy human volunteers. They found that 
multishot EPI had less qualitative distortion and less quantitative difference between right and left optic 
nerves and was more reproducible at a higher resolution when compared to single shot EPI. 
Comparatively, our study is the first to our knowledge to report findings on multishot EPI techniques 
between healthy volunteers and NF1 children with and without tumors. Our findings are similar in 
demonstrating the improvement for multishot EPI for delineating increases in tract volume and number 
compared to single shot EPI. However, there are significant differences in analysis. We used a tract-
based analysis based on seeding from the optic tracts and chiasm, which would have less distortion than 
the prechiasmatic optic nerve due to the proximity of the bone and sinuses. Jeong et al placed ROIs on 
the optic nerves of the mean diffusivity map which can be susceptible to distortion and may affect ROI 
accuracy.   
There have been prior reports on the use of DTI in the optic pathway for NF1 patients; however, 
none of these have addressed the problem of susceptibility artifact affecting the quantification of 
parameters in the anterior pathway of the optic nerve and chiasm. In a mouse model genetically 
engineered to develop NF1 and OG, Hegedus et al [12] demonstrated progressive decreased FA and 
increased RD from three weeks to six months as OG developed. No difference was demonstrated 
between these NF1 mice and wild type mice before 3 weeks, the time frame before OG developed.  It is 
important to note that in this mouse study, Hegedus et al used a conventional spin echo technique 
instead of echo planar imaging to perform DTI, which would require long scanning times not practical for 
clinical use but does not suffer from susceptibility artifacts.  Furthermore, the technical comparison of 
mouse anatomy to human anatomy would also be difficult regarding susceptibility artifact at the skull 
base. In human subjects, Filippi et al [13] and Nickerson et al [14] in related studies on 9 NF1 patients 
and 44 and 70 controls respectively, report quantitative data for optic nerve FA, MD and ADC. They used 
conventional single shot EPI and marked small voxel ROIs for the optic nerves on T2 weighted anatomic 
images, with no comment about how the susceptibility artifact was overcome. Data from this voxel-
based approach may be less reliable as using T1 or T2 weighted anatomic images for ROI placement 
would be less likely to translate appropriately to the distortion on EPI images from susceptibility. Again, 
we used a tract-based approach, which depends on mathematical analysis to generate tracts with less 
dependence on image registration [15]. 
Similarly, de Blank et al [16] also used a tract-based approach and report that FA decrease is 
associated with visual acuity loss in NF1 patients versus NF1 patients without visual loss as controls. 
However, they found the significant FA decrease only in the optic radiations but not in the optic nerves. 
In their discussion they write: "Small white matter structures, such as optic nerves and tracts, can be 
difﬁcult to isolate on DTI without partial voluming, and these pathways may be subject to susceptibility 
artifacts. The lack of a significant difference in FA of these structures may be attributable to the difﬁculty 
in measuring these anterior pathways accurately." This emphasizes the importance of using a technique 
which is high resolution and limits the susceptibility artifact of the anterior skull base. While 
quantification of distal but connected tracts such as the optic radiations will likely produce a change, 
assessment of the fibers at or immediately adjacent to tumor development will likely produce the 
highest sensitivity in association with visual loss. This is similar to a study by Ellingson et al [17], where 
DTI measures were performed on ten subjects with chronic spinal cord injury showing the greatest 
decrease in FA and greatest increase in diffusivity measures at or immediately adjacent to the level of 
injury compared to healthy controls.  At levels more remote from the site of spinal cord injury, the 
differences in these measures were less pronounced, suggesting the greatest sensitivity of correlating 
with function lies near the site of injury.  
Further implications from this study suggests that a DTI technique with increased resolution and 
less susceptibility artifact would be a better choice for studies where quantitative evaluation of the optic 
nerve can serve as a biomarker for visual function in very young children, and as a measure of improving 
health of the optic nerve with treatment.  
Comparison between patient groups 
Although we were able to demonstrate the technical superiority of rsDTI in delineating the optic 
nerves with adequate power, we were only able to find a significant decrease in mean, axial and radial 
diffusivity in NF1 patients with visual symptoms and chemotherapy, compared to NF1 patients without 
visual symptoms or chemotherapy. This contradicts the previous literature of increased mean and radial 
diffusivity associated with visual loss or pathology due to optic tumors [13, 14, 16, 18]. Furthermore, this 
significant decrease in diffusivity was only found on the conventional ssDTI scans and not the rsDTI 
technique. Although this result may be spurious due to the inadequate power of NF1 subjects measured 
with and without visual symptoms, Ellingson et al [17] also detected the finding of decreased diffusivity 
cranial to the site of spinal cord injury but not caudal. This has also been demonstrated in animal models 
and has been postulated to be related to chronic changes of axonal restructuring and widespread cord 
degeneration. Previous or concurrent chemotherapy also showed similar decreases in diffusivity; 
however, as the visual symptom and chemotherapy groups were nearly identical except for one subject, 
we cannot isolate the chemotherapy effect on the diffusivity parameter. De Blank et al [19] was able to 
find a significant decrease in FA of the central white matter tracts of the brain in NF1 patients treated 
with vincristine and carboplatin compared to NF1 patients without prior treatment. Although we could 
expect FA to decrease in our patients with chemotherapy and visual symptoms compared to controls, 
we did not find a significant difference for the FA of the optic nerves in our study. Although we had 
enough power to demonstrate the technical superiority of rsDTI to ssDTI, we likely did not have enough 
power to demonstrate an effect of decreased optic nerve integrity as represented by the presence of 
visual symptoms.  Another factor is the decision to calculate the bilateral optic nerves as merged tracts 
per patient instead of individually. This is due to the greater propensity of NF1 OG to involve the optic 
chiasm, which would theoretically affect quantitative parameters for both optic nerves. Accordingly, our 
study also showed most optic gliomas involving the chiasm, with only 2/6 with visual symptoms 
demonstrating unilateral optic nerve glioma on MRI.  
Limitations 
Our study had inadequate power to assess for differences between patient groups. Further 
study with larger power is needed to confirm quantifiable differences correlated to visual symptoms.  
While rsDTI represents an improvement for EPI based techniques at limiting susceptibility artifact, we 
still noticed a small amount of distortion, particularly for older patients where the size of the sphenoid 
sinus allowed a greater amount of air near the anatomy of interest. A robust DTI technique with limited 
inherent susceptibility artifact such as spin echo techniques at clinically acceptable scan times may 
ultimately be a better alternative. 12-minute scan times for a single sequence is also limited in clinical 
usefulness. Newer technology using simultaneous multi-slice may decrease imaging time by greater than 
50%, depending on the acceleration factor, but comes at the cost of slice signal leakage from aliasing 
[20].  
Conclusion:  
High resolution DTI with readout-segmented multi-shot EPI technique can better visualize the 
optic pathway, particularly the optic nerve and chiasm, which can be affected by susceptibility artifact. 
This is shown by a significant increase in FA, tract count, and volume with rsDTI versus ssDTI.  This may 
allow more confident measurements of anisotropy and diffusivity in NF1 patients who develop OG with 
visual deficits and may serve as a marker for treatment initiation and follow-up.   
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Subject Age at 
MRI 
(yrs) 
NF1 Optic Pathway 
Tumor 
Visual 
symptoms 
Chemotherapy 
1 9 Y Y  Y- Left eye 
decreased 
vision 
Y  
2 7 Y Y N N 
3 13 Y Y  N N 
4 14 Y Y  Y- right vision 
loss 
Y 
5 3 Y Y  Y- nystagmus 
and worsening 
vision 
Y 
6 7 Y Y  N N  
7 3 Y N N N 
8 15 Y Y  Y- Left eye 
decreased 
vision 
Y  
9 18 Y  Y N N 
10 7 Y Y N N 
11 6 Y N N N 
12 11 Y Y  Y – left eye 
decreased 
vision 
Y  
13 12 Y  Y  Y - decreased 
vision, 
nystagmus 
Y  
14 12 Y N N Y  
15 13 Y N N N 
16 12 Y N N N 
17 8 Y N N N 
18 7 Y Y N N 
19 2 Y N N N 
HC 5 N N N N 
HC 5 N N N N 
HC 4 N N N N 
HC 3 N N N N 
HC 17 N  N N N 
 
Table 1. Subject characteristics.  All subjects with chemotherapy had vincristine and carboplatin, except 
for subject 14 who received sunitinib malate as part of a trial for plexiform neurofibromas. 
 
 Scan Type   
Tract Count 
 
Tract 
Length 
Tract 
Volume FA MD AD RD 
All Subjects 
ssDTI 978.8 ± 172.9 5.6 ± 0.6 488.8 ± 72.0 0.29 ± 0.01 1.94 ± 0.07 2.42 ± 0.08 1.69 ± 0.07 
rsDTI 2055.0 ± 205.9 7.9 ± 1.1 977.8 ± 96.1 0.40 ± 0.01 1.55 ± 0.08 2.15 ± 0.10 1.26 ± 0.07 
p-value  <0.001 0.044 <0.001 <0.001 <0.001 0.036 <0.001 
Table 2. Comparison of ssDTI and rsDTI for all subjects including healthy controls. Data reported as mean 
± standard error with significant p-values from two-tailed paired t-test bolded. 
 
 Scan Type   
Tract Count 
 
Tract 
Length 
Tract 
Volume FA MD AD RD 
Healthy 
Control 
ssDTI  1182.8 ± 145.9 
6.8 ± 
1.5 
686.8 ± 
178.7 0.29 ± 0.02 1.92 ± 0.13 2.42 ± 0.13 1.68 ± 0.12 
rsDTI 1812.8 ± 539.5 
10.0 ± 
5.1 
709.8 ± 
198.6 0.41 ± 0.02*  
1.77 ± 0.20 2.43 ± 0.24 1.44 ± 0.18 
 p-value 0.219 0.219 0.639 <0.001 0.339 0.960 0.135 
NF_1 + No 
Tumor 
ssDTI  849.9 ± 291.9 6.3 ± 1.2 
476.0 ± 
133.7 0.30 ± 0.01 1.91 ± 0.07 2.39 ± 0.09 1.67 ± 0.07 
rsDTI  2204.5 ± 322.3*  
7.8 ± 
1.6 
942.3 ± 
153.0*  0.38 ± 0.02*  
1.52 ± 
0.10*  2.09 ± 0.13 1.24 ± 0.08*  
 p-value 0.004 0.575 0.009 0.002 0.019 0.115 0.006 
NF_1 + 
Tumor 
ssDTI  968.9 ± 303.7 4.8 ± 0.8 413.8 ± 95.8 0.28 ± 0.02 1.96 ± 0.14 2.44 ± 0.15 1.72 ± 0.14 
rsDTI  2061.6 ± 313.7*  
7.1 ± 
1.0 
1094.9 ± 
143.2*  0.41 ± 0.02*  
1.49 ± 
0.12*  
2.08 ± 
0.15*  1.20 ± 0.10*  
 p-value 0.002 0.236 <0.001 <0.001 0.002 0.041 <0.001 
Table 3. Comparison of scan types (ssDTI versus rsDTI) within patient groups. Data reported as mean +/- 
standard Error of Mean. * Significant rsDTI vs. ssDTI within patient groups. 
 
 
 
 
 
 
 
 Scan Type   
Tract Count 
 
Tract 
Length Tract Volume FA MD AD RD 
Healthy 
Control 
ssDTI  1182.8 ± 145.9  6.8 ± 1.5 686.6 ± 178.7 0.29 ± 0.02 
1.92 ± 
0.13 
2.42 ± 
0.13 1.68 ± 0.12 
rsDTI  1812.8 ± 539.5 10.0 ± 5.1 709.8 ± 198.6 
0.41 ± 
0.02*  
1.77 ± 
0.20 
2.43 ± 
0.24 1.44 ± 0.18 
 p-value 0.221 0.222 0.652 0.001 0.344 0.974 0.131 
NF_1 + No 
Visual 
ssDTI  1073.3 ± 291.4 5.1 ± 0.8 449.5 ± 88.2 0.27 ± 0.01 2.09 ± 0.10 2.57 ±0.11 1.85 ± 0.10 
rsDTI  2289.3 ± 265.0* 7.2 ± 1.2 
1015.5 ± 
149.3*  
0.39 ± 
0.02*  
1.58 ± 
0.10*  
2.17 ± 
0.13*  
1.28 ± 
0.09* 
 p-value 0.001 0.356 <0.001 <0.001 <0.001 0.016 <0.001 
NF_1 + 
Visual 
ssDTI  603.8 ± 235.5 5.8 ± 1.3 408.8 ± 158.9 0.31 ± 0.02 1.64 ± 0.09 
2.11 ± 
0.11 1.40 ± 0.09 
rsDTI  1787.2 ± 421.1*  7.7 ± 1.0 
1088.0 ± 
138.6*  
0.42 ± 
0.03*  
1.37 ± 
0.14 
1.91 ± 
0.17 1.10 ± 0.13 
 p-value 0.015 0.390 0.001 0.001 0.099 0.291 0.047 
Table 4. Comparison of scan types (ssDTI versus rsDTI) in healthy controls and NF1 patients with and 
without visual symptoms. Data reported as mean +/- standard Error of Mean. * Significant rsDTI vs. 
ssDTI within patient groups. 
 
 Scan Type   
Tract Count 
 
Tract 
Length Tract Volume FA MD AD RD 
NF_1  No 
Chemo 
ssDTI  1069.8 ± 316.8 5.0 ± 0.9 433.0 ± 94.2 0.27 ± 0.01 2.12 ± 0.11 2.60 ± 0.12 1.87 ± 0.10 
rsDTI  2234.3 ± 286.6*  
7.04 ± 
1.3 
1047.3 ± 
161.3*  0.40 ± 0.02*  1.55 ± 0.11*  2.15 ± 0.14*  1.25 ± 0.09*  
p-value  0.003 0.066 <0.001 <0.001 <0.001 0.020 <0.001 
NF_1 + 
Chemo 
ssDTI  676.9 ± 212.0 5.72 ± 1.1 443.1 ± 138.6 0.31 ± 0.02 1.66 ± 0.08 2.14 ± 0.09 1.43 ± 0.08 
rsDTI  1937.4 ± 386.3*  
7.8 ± 
0.85 
1031.9 ± 
129.7*  0.41 ± 0.02*  1.43 ± 0.13 2.00 ± 0.16 1.16 ± 0.12 
p-value  0.032 0.050 0.024 0.002 0.166 0.411 0.089 
Table 5. Comparison of NF1 subjects with and without prior or concurrent chemotherapy. Data reported 
as mean ± standard error. * significant rsDTI vs. ssDTI within patient groups 
 
 
 
 Scan Type   
Tract Count 
 
Tract 
Length Tract Volume FA MD AD RD 
Healthy 
Control ssDTI  1182.8 ± 145.9 6.8 ± 1.5 686.6 ± 178.7 0.29 ± 0.02 
1.92 ± 
0.13 
2.42 ± 
0.13 1.68 ± 0.12 
HC vs NF_1 
+ No Visual p-value 0.810 0.426 0.267 0.467 0.371 0.435 0.344 
NF_1 + No 
Visual ssDTI  1073.3 ± 291.4 5.1 ± 0.8 449.5 ± 88.2 0.27 ± 0.01 
2.09 ± 
0.10 2.57 ±0.11 1.85 ± 0.10 
HC vs NF_1 
+ Visual p-value 0.928 0.472 0.286 0.955 0.109 0.091 0.129 
NF_1 + 
Visual ssDTI  603.8 ± 235.5 5.8 ± 1.3 408.8 ± 158.9 0.31 ± 0.02 
1.64 ± 
0.09†  
2.11 ± 
0.11†  
1.40 ± 
0.09†  
NF_1 + No 
Visual vs 
NF_1 + 
Visual  
p-value 0.278 0.837 0.694 0.123 0.011 0.016 0.010 
Table 6: Comparison between healthy controls and NF1 patients with and without visual symptoms for 
ssDTI scan type. Data reported as mean +/- standard Error of Mean. † significant between NF1 patients 
without and with visual symptoms. 
 
 Scan Type   
Tract Count 
 
Tract 
Length Tract Volume FA MD AD RD 
NF_1  No 
Chemo ssDTI  
1069.8 ± 
316.8 5.0 ± 0.9 433.0 ± 94.2 0.27 ± 0.01 2.12 ± 0.11 2.60 ± 0.12 1.87 ± 0.10 
NF_1 + 
Chemo ssDTI  676.9 ± 212.0 
5.72 ± 
1.1 443.1 ± 138.6 0.31 ± 0.02 1.66 ± 0.08† 2.14 ± 0.09† 1.43 ± 0.08† 
p-value  0.393 0.651 0.951 0.072 0.009 0.012 0.008 
Table 7: Comparison of ssDTI scans for NF_1 subjects with and without concurrent chemotherapy. 
†Significant between NF1 patients with and without chemotherapy. 
 
   Tract Count Tract Length 
Tract 
Volume FA MD AD RD 
All Subjects 
Observed 
Power 0.976 0.368 0.971 0.999 0.937 0.567 0.990 
Partial 
Eta2 0.274 0.062 0.270 0.605 0.233 0.101 0.315 
 
Table 8: Observed Power Analysis using α = 0.05 and estimated effect size between ssDTI and rsDTI 
between all subjects. 
  Tract Count Tract Length 
Tract 
Volume FA MD AD RD 
ssDTI vs 
rsDTI 
Observed 
Power 0.917 0.372 0.827 0.999 0.795 0.339 0.940 
Partial 
Eta2 0.232 0.069 0.189 0.571 0.177 0.062 0.255 
Healthy 
Control, 
NF_1 +/- 
Tumor 
Observed 
Power 0.050 0.209 0.074 0.068 0.112 0.141 0.096 
Partial 
Eta2 0.000 0.049 0.009 0.007 0.021 0.030 0.016 
 
Table 9: Observed Power Analysis using α = 0.05 and estimated effect size within patient groups for scan 
type (ssDTI vs rsDTI) and between patient groups (healthy controls, NF_1 patients without tumors, and 
NF1 patients with tumors) for each scan type. 
 
 
 
 
 
 
  
Figure 1: A. Fractional anisotropy map shows ROIs placed in the bilateral optic tracts and within the 
expected epicenter of the chiasm involved by tumor. B. Axial T1 weighted anatomical image of the same 
patient showing the optic chiasm glioma (arrow). 
 Figure 2: A. Seeding placed on both optic tracts (purple and green) with region of interest on the chiasm 
(red). B. Tracts generated from both left and right optic tract seeds and the chiasm. C. Trimming of tracts 
behind the optic chiasm. D. Merging of right and left tracts. 
 
 
  
Figure 3: ssDTI (A) vs rsDTI (B) on FA maps of subject 16. Note the improvement in susceptibility 
distortion of the optic chiasm and tracts (arrows) on the rsDTI image.  There is also less distortion of the 
globes. 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 1 
 
 Scan Type   
Tract Count 
 
Tract 
Length 
Tract 
Volume FA MD AD RD 
Healthy 
Control  ssDTI  
1182.8 ± 
145.9 
6.8 ± 
1.5 
686.8 ± 
178.7 0.29 ± 0.02 1.92 ± 0.13 2.42 ± 0.13 1.68 ± 0.12 
HC vs NF_1 
No Tumor p-value 0.524 0.819 0.313 0.786 0.932 0.893 0.955 
NF_1 + No 
Tumor ssDTI  849.9 ± 291.9 
6.3 ± 
1.2 
476.0 ± 
133.7 0.30 ± 0.01 1.91 ± 0.07 2.39 ± 0.09 1.67 ± 0.07 
HC vs NF_1 
+ Tumor p-value 0.652 0.298 0.197 0.588 0.927 0.974 0.901 
NF_1 + 
Tumor ssDTI  968.9 ± 303.7 
4.8 ± 
0.8 413.8 ± 95.8 0.28 ± 0.02 1.96 ± 0.14 2.44 ± 0.15 1.72 ± 0.14 
NF_1 + No 
Tumor vs 
NF_1 
+Tumor 
p-value 0.778 0.372 0.820 0.354 0.837 0.841 0.836 
Table A1: Comparison between healthy controls and NF1 patients with and without optic pathway 
tumors for ssDTI scan type. Data reported as mean +/- standard Error of Mean.  
 
 Scan Type   
Tract Count 
 
Tract 
Length 
Tract 
Volume FA MD AD RD 
Healthy 
Control  rsDTI 
1812.8 ± 
539.5 
10.0 ± 
5.1 
709.8 ± 
198.6 0.41 ± 0.02  
1.77 ± 0.20 2.43 ± 0.24 1.44 ± 0.18 
HC vs NF_1 
No Tumor p-value 0.512 0.441 0.539 0.380 0.326 0.279 0.369 
NF_1 + No 
Tumor rsDTI  
2204.5 ± 
322.3 
7.8 ± 
1.6 
942.3 ± 
153.0 0.38 ± 0.02  1.52 ± 0.10  2.09 ± 0.13 1.24 ± 0.08  
HC vs NF_1 
+ Tumor p-value 0.661 0.316 0.202 0.911 0.314 0.285 0.339 
NF_1 + 
Tumor rsDTI 
2061.6 ± 
313.7 
7.1 ± 
1.0 
1094.9 ± 
143.2  0.41 ± 0.02  1.49 ± 0.12  2.08 ± 0.15 1.20 ± 0.10  
NF_1 + No 
Tumor vs 
NF_1 + 
Tumor 
p-value 0.741 0.855 0.480 0.325 0.929 0.882 0.967 
Table A2: Comparison between healthy controls and NF1 patients with and without optic pathway 
tumors for rsDTI scan type. Data reported as mean +/- standard Error of Mean.  
 
 
 Scan Type   
Tract Count 
 
Tract 
Length Tract Volume FA MD AD RD 
Healthy 
Control rsDTI  1812.8 ± 539.5 
10.0 ± 
5.1 709.8 ± 198.6 0.41 ± 0.02 
1.77 ± 
0.20 
2.43 ± 
0.24 1.44 ± 0.18 
HC vs NF_1 
+ No Visual p-value 0.377 0.304 0.323 0.547 0.448 0.403 0.487 
NF_1 + No 
Visual rsDTI  2289.3 ± 265.0 7.2 ± 1.2 
1015.5 ± 
149.3 0.39 ± 0.02 
1.58 ± 
0.10 
2.17 ± 
0.13 1.28 ± 0.09 
HC vs NF_1 
+ Visual p-value 0.928 0.472 0.286 0.955 0.109 0.091 0.129 
NF_1 + 
Visual rsDTI  1787.2 ± 421.1 7.7 ± 1.0 
1088.0 ± 
138.6 0.42 ± 0.03 
1.37 ± 
0.14 
1.91 ± 
0.17 1.10 ± 0.13 
NF_1 + No 
Visual vs 
NF_1 + 
Visual 
p-value 0.264 0.781 0.814 0.448 0.228 0.216 0.243 
Table A3: Comparison between healthy controls and NF1 patients with and without visual symptoms for 
rsDTI scan type. Data reported as mean +/- standard Error of Mean.  
 
 
 Scan Type   
Tract Count 
 
Tract 
Length Tract Volume FA MD AD RD 
NF_1  No 
Chemo rsDTI  
2234.3 ± 
286.6 
7.04 ± 
1.3 
1047.3 ± 
161.3 0.40 ± 0.02 1.55 ± 0.11 2.15 ± 0.14 1.25 ± 0.09 
NF_1 + 
Chemo rsDTI  
1937.4 ± 
386.3 
7.8 ± 
0.85 
1031.9 ± 
129.7 0.41 ± 0.02 1.43 ± 0.13 2.00 ± 0.16 1.16 ± 0.12 
p-value  0.537 0.672 0.945 0.829 0.484 0.437 0.527 
 
Table A4: Comparison of rsDTI scans for NF_1 subjects with and without concurrent chemotherapy.  
 
 
